BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1073 related articles for article (PubMed ID: 12832099)

  • 1. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
    Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
    Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
    Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
    J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ; Kemmeries G; Holst JJ; Nauck MA
    Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.
    Vilsbøll T; Krarup T; Deacon CF; Madsbad S; Holst JJ
    Diabetes; 2001 Mar; 50(3):609-13. PubMed ID: 11246881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
    Kuwata H; Iwasaki M; Shimizu S; Minami K; Maeda H; Seino S; Nakada K; Nosaka C; Murotani K; Kurose T; Seino Y; Yabe D
    Diabetologia; 2016 Mar; 59(3):453-61. PubMed ID: 26704625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Jensen MH; Gabe MBN; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetes; 2019 May; 68(5):906-917. PubMed ID: 30626611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    Digestion; 1992; 52(3-4):214-21. PubMed ID: 1459356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.
    Nauck M; Schmidt WE; Ebert R; Strietzel J; Cantor P; Hoffmann G; Creutzfeldt W
    J Clin Endocrinol Metab; 1989 Sep; 69(3):654-62. PubMed ID: 2668324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
    Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
    Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
    Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
    J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.